Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10849900-B2
Publication Date
2020-12-01
Expiration Date
Abstract
A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.
Core Innovation
The disclosed method combines selective internal radiation therapy (SIRT) with a staged chemotherapy regimen containing oxaliplatin, leucovorin, and 5-fluorouracil for treatment of a cancer patient. The regimen uses reduced-dose oxaliplatin in initial chemotherapy cycles, followed by SIRT and subsequent chemotherapy with a higher oxaliplatin dose. The disclosure identifies colorectal cancer liver metastases as a particular treatment context.
The regimen aims to limit hepatotoxicity associated with combining oxaliplatin and selective internal radiation therapy while enhancing the antitumor effect of selective internal radiation therapy. The method sequences the delivery of chemotherapy cycles around radiation administration to balance therapeutic efficacy and toxicological impact. Specific background problems and abstract summaries remain not explicitly described in patent.
Claims Coverage
The provided relevant claims identify one independent claim with two inventive features.
Combination of staged chemotherapy and SIRT
A cancer treatment method combines oxaliplatin, leucovorin, and 5-fluorouracil chemotherapy with SIRT. The chemotherapy is staged, with a lower oxaliplatin dose in the initial cycles and a higher dose in a subsequent chemotherapy regime.
Timing and sequence of treatment
The claim specifies SIRT in relation to the commencement or repetition of the initial chemotherapy regime, followed by three cycles of that regime and then a second chemotherapy regime.
The independent claim covers a combined SIRT and chemotherapy method, emphasizing staged oxaliplatin dosing and the sequence of the initial chemotherapy, SIRT, and subsequent chemotherapy.
Stated Advantages
The regimen is intended to limit hepatotoxicity associated with combining oxaliplatin and SIRT while enhancing SIRT's antitumor effect.
The reported study found median progression-free survival of approximately 12.5 months with chemotherapy plus SIRT, compared with 9.4 months with chemotherapy plus bevacizumab alone, with a reported hazard ratio of 0.75.
Documented Applications
Treatment of cancer, particularly colorectal cancer liver metastases, using a combination of staged chemotherapy and selective internal radiation therapy.
Interested in licensing this patent?